Aptamer Proteomics for Biomarker Discovery in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Proteomic SubstudyJOURNAL OF THE AMERICAN HEART ASSOCIATIONIF5.32024-07-021OAAI
Clinical characteristics of heart failure with reduced ejection fraction patients with rare pathogenic variants in dilated cardiomyopathy-associated genes: A subgroup analysis of the PARADIGM-HF trialEUROPEAN JOURNAL OF HEART FAILUREIF10.82023-06-013OA
A proteogenomic view of Parkinson's disease causality and heterogeneityNPJ PARKINSONS DISEASEIF8.22023-02-1122OAAI
Aptamer Proteomics for Biomarker Discovery in Heart Failure With Reduced Ejection FractionCIRCULATIONIF38.62022-11-0117OA
The genomics of heart failure: design and rationale of the HERMES consortium心力衰竭的基因组学: HERMES财团的设计和原理ESC HEART FAILUREIF3.72021-09-0312OA
Application of Large-Scale Aptamer-Based Proteomic Profiling to Planned Myocardial InfarctionsCIRCULATIONIF38.62018-03-2042OAAI
Modification of proteins in vitro by physiological levels of glucose -: Pyridoxamine inhibits conversion of Amadori intermediate to advanced glycation end-products through binding of redox metal ionsJOURNAL OF BIOLOGICAL CHEMISTRYIF3.92003-11-01130OAAI